Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Buchtitelbild

2018 | OriginalPaper | Buchkapitel

1. Multiple Sklerose und andere autoimmune ZNS-Erkrankungen

verfasst von : Martin Stangel, Christoph Kleinschnitz, Mathias Mäurer, Peter Raab, Kurt-Wolfram Sühs, Corinna Trebst

Erschienen in: Autoimmunerkrankungen in der Neurologie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Autoimmunerkrankungen des zentralen Nervensystems (ZNS) stellen eines der sich am schnellsten entwickelnden Gebiete in der Neurologie dar. Die Entdeckung neuer Autoantikörper hat zur Beschreibung neuer Krankheitsentitäten und zu einer Diversifizierung geführt, die einerseits eine gute differenzialdiagnostische Abgrenzung erfordert, ebenso wie es zu unterschiedlichen Therapieschemata führt. Aber auch klassische Erkrankungen wie die Multiple Sklerose haben mit der Abgrenzung der Neuromyelitis-Optica-Spektrumerkrankungen neue Impulse erhalten. Parallel dazu gab es eine beeindruckende Entwicklung bei den Immuntherapeutika, sodass für diese Erkrankungen unterschiedlichste Therapieoptionen bestehen.
Literatur
Alusi SH, Worthington J, Glickman S, Bain PG (2001) A study of tremor in multiple sclerosis. Brain 124:720–730PubMedCrossRef
Ascherio A, Munger KL (2016) Epidemiology of multiple sclerosis: from risk factors to prevention – an update. Semin Neurol 36(2):103–114PubMedCrossRef
Capello E, Mancardi GL (2004) Marburg type and Balo’s concentric sclerosis: rare and acute variants of multiple sclerosis. Neurol Sci 25(Suppl 4):361–363CrossRef
Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7:1139–1151PubMedCrossRef
Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9: 438–446PubMedCrossRef
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, and Kappos L (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402–415CrossRef
Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786–1801
Comi G, De SN, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM et al (2012) Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 11 (1): 33–41PubMedCrossRef
Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, and Filippi M (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374: 1503–1511CrossRef
Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, and Filippi M (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371: 2085–2092CrossRef
Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T (1998) Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple sclerosis group. N Engl J Med 339:285–291PubMedCrossRef
Dippel FW, Mäurer M, Schinzel S, Müller-Bohn T, Larisch K (2015) Krankenversicherungsdaten bestätigen hohe Prävalenz der Multiplen Sklerose. Akt Neurol 42(4):191–196CrossRef
Esposito S, Bonavita S, Sparaco M, Gallo A, Tedeschi G (2017) The role of diet in multiple sclerosis: a review. Nutr Neurosci 24:1–14
Filippi M, Rocca MA, Ciccarelli O et al (2016) MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 15:292–303PubMedPubMedCentralCrossRef
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367 (12): 1087–1097
Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S (2005) The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 4:111–121PubMedCrossRef
Garren H, Robinson WH, Krasulova E, Havrdova E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L (2008) Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 63: 611–620PubMedCrossRef
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg SP, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362: 416–426CrossRef
Gold R et al (2012) Diagnose und Therapie der Multiplen Sklerose. Leitlinie der Deutschen Gesellschaft für Neurologie, www.​dgn.​org
Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367 (12): 1098–1107CrossRef
Hartung HP, Aktas O, Menge T, Kieseier BC (2014) Immune regulation of multiple sclerosis. Handb Clin Neurol 122:3–14PubMedCrossRef
Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360: 2018–2025CrossRef
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B et al (2017) Ocrelizumab versus Interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376 (3): 221–234CrossRef
Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676–688CrossRef
Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser SL, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH (2009) Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66: 460–471PubMedCrossRef
Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth SG (2017) What is new in symptomatic MS treatment: Part 1-introduction and methodical approach, ataxia and tremor. Nervenarzt 88 (12): 1421–1427PubMedCrossRef
Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth SG (2017) What is new in symptomatic MS treatment: Part 2-gait disorder and spasticity. Nervenarzt 88 (12): 1428–1434PubMedCrossRef
Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth SG (2018) What is new in symptomatic MS treatment: Part 3-bladder dysfunction. Nervenarzt 89 (2): 184–192
Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth SG (2018) New aspects of symptomatic MS treatment: Part 4-sexual dysfunction and eye movement disorders. Nervenarzt 89 (2): 193–197
Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth SG (2017) New aspects of symptomatic MS treatment: Part 6 – cognitive dysfunction and rehabilitation. Nervenarzt. https://​10.​1007/​s00115-017-0443-7
Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, and Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343: 898–904
Jörg S, Grohme DA, Erzler M, Binsfeld M, Haghikia A, Müller DN, Linker RA, Kleinewietfeld M (2016) Environmental factors in autoimmune diseases and their role in multiple sclerosis. Cell Mol Life Sci 73(24):4611–4622PubMedPubMedCentralCrossRef
Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, and Miller DH (2010) Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 9: 681–688PubMedCrossRef
Kappos L, Edan G, Freedman MS, Montalban X, Hartung HP, Hemmer B et al (2016) The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology 87 (10): 978–987PubMedPubMedCentralCrossRef
Kappos L, Li D, Calabresi PA, O‘Connor P, Bar-Or A, Barkhof F et al (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378 (9805): 1779–1787CrossRef
Kappos L, Radue EW, O‘Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, and Burtin P (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387–401CrossRef
Kleinschnitz C, Meuth SG, Kieseier BC, Wiendl H (2007) Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis. Nervenarzt 78:883–911PubMedCrossRef
Klotz L, Berthele A, Brück W, Chan A, Flachenecker P, Gold R, Haghikia A, Hellwig K, Hemmer B, Hohlfeld R, Korn T, Kümpfel T, Lang M, Limmroth V, Linker RA, Meier U, Meuth SG, Paul F, Salmen A, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber MS, Ziemssen T, Zipp F, Wiendl H (2016) Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action. Nervenarzt 87 (6): 645–659PubMedCrossRef
Koch M, Uyttenboogaart M, Polman S, De Keyser J (2008) Seizures in multiple sclerosis. Epilepsia 49:948–953PubMedCrossRef
Kolber P, Luessi F, Meuth SG, Klotz L, Korn T, Trebst C, Tackenberg B, Kieseier B, Kümpfel T, Fleischer V, Tumani H, Wildemann B, Lang M, Flachenecker P, Meier U, Brück W, Limmroth V, Haghikia A, Hartung HP, Stangel M, Hohlfeld R, Hemmer B, Gold R, Wiendl H, Zipp F (2015) [Current aspects of therapy conversion for multiple sclerosis]. Nervenarzt 86 (10): 1236–1247PubMedCrossRef
Leake JA, Albani S, Kao AS et al (2004) Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 23:756–764PubMedCrossRef
Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83:1–9CrossRef
McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, Nicholas R, Palace J, Pearson OR, Rog D, Young CA (2016) Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 87 (2): 117–125
Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F (2018) ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 24 (2): 96–120PubMedCrossRef
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 376 (3): 209–220CrossRef
Moore P, Harding KE, Clarkson H, Pickersgill TP, Wardle M, Robertson NP (2013) Demographic and clinical factors associated with changes in employment in multiple sclerosis. Mult Scler 19(12):1647–1654PubMedCrossRef
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. New Engl J Med 343:938–952PubMedCrossRef
O’Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP et al (2016) Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. Neurology 86 (10): 920–930PubMedPubMedCentralCrossRef
Pender MP, Burrows SR (2014) Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy. Clin Transl Immunology 3(10):e27PubMedPubMedCentralCrossRef
Petersen G, Wittmann R, Arndt V, Göpffarth D (2014) Epidemiologie der Multiplen Sklerose in Deutschland. Nervenarzt 85:990–998PubMedCrossRef
Pierrot-Deseilligny C, Souberbielle JC (2017) Vitamin D and multiple sclerosis: an update. Mult Scler Relat Disord 14:35–45PubMedCrossRef
Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, and Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910CrossRef
Polman CH, Reingold SC, Banwell B et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the „McDonald Criteria“ Ann Neurol 69:292–302PubMedPubMedCentralCrossRef
Poser CM, Goutieres F, Carpentier MA, Aicardi J (1986) Schilder’s myelinoclastic diffuse sclerosis. Pediatrics 77:107–112PubMed
Rao SM, Leo GJ, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41:685–691PubMedCrossRef
Rolak LA, Fleming JO (2007) The differential diagnosis of multiple sclerosis. Neurologist 13:57–72PubMedCrossRef
Rovira A, Wattjes MP, Tintore M et al (2015) Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol 11:471–482PubMedCrossRef
Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911–923CrossRef
Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS et al (2013) Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 12 (8): 756–767PubMedCrossRef
Selter RC, Hemmer B (2013) Update on immunopathogenesis and immunotherapy in multiple sclerosis. Immunotargets Ther 2:21–30PubMedPubMedCentral
Seze J de, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, and Vermersch P (2004) Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler 10: 596–597PubMedCrossRef
Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci E, Giuliani G, Sola P, Spitaleri DL, Lechner-Scott J, Bergamaschi R, Grand'Maison F, Granella F, Kappos L, Trojano M, Butzkueven H (2016) Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. Neurol Clin Pract 6 (2): 102–115
Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci E, Giuliani G, Sola P, Spitaleri DL, Lechner-Scott J, Bergamaschi R, Grand'Maison F, Granella F, Kappos L, Trojano M, Butzkueven H (2016) Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. Neurol Clin Pract 6 (2): 102–115
Seze J de, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, and Vermersch P (2004) Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler 10: 596–597PubMedCrossRef
Stangel M, Penner IK, Kallmann BA, Lukas C, Kieseier BC (2015) Towards the implementation of ‚no evidence of disease activity‘ in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord 8 (1): 3–13CrossRef
Swingler RJ, Compston DA (1992) The morbidity of multiple sclerosis. Q J Med 83:325–337PubMed
Tenembaum S, Chitnis T, Ness J, Hahn JS (2007) Acute disseminated encephalomyelitis. Neurology 68:23–36CrossRef
Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–73
The optic neuritis study group (2008) Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 65:727–732PubMedCentral
Tranchant C, Bhatia KP, Marsden CD (1995) Movement disorders in multiple sclerosis. Mov Disord 10:418–423PubMedCrossRef
Williamson EML, Berger JR (2017) Diagnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies. Neurotherapeutics 14 (4): 961–973PubMedCrossRefPubMedCentral
Xia L, Lin S, Wang ZC et al (2009) Tumefactive demyelinating lesions: nine cases and a review of the literature. Neurosurg Rev 32:171–179PubMedCrossRef
Yadav SK, Mindur JE, Ito K, Dhib-Jalbut S (2015) Advances in the immunopathogenesis of multiple sclerosis. Curr Opin Neurol 28(3):206–219PubMedCrossRef
Zimmermann C, Hohlfeld R (1999) ‘Fatigue’ in multiple sclerosis. Nervenarzt 70:566–574
Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M et al (2014) Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82(15):1302–1306PubMedPubMedCentralCrossRef
Ayzenberg I, Schollhammer J, Hoepner R, Hellwig K, Ringelstein M, Aktas O et al (2016) Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. J Neurol 263(3):575–582PubMedCrossRef
Bichuetti DB, Oliveira EM, Boulos FC, Gabbai AA (2012) Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. Arch Neurol 69(7):938–939PubMedCrossRef
Bizzoco E, Lolli F, Repice AM, Hakiki B, Falcini M, Barilaro A et al (2009) Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 256(11):1891–1898PubMedCrossRef
Chitnis T, Ness J, Krupp L, Waubant E, Hunt T, Olsen CS et al (2016) Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology 86(3):245–252PubMedPubMedCentralCrossRef
Elsone L, Kitley J, Luppe S, Lythgoe D, Mutch K, Jacob S et al (2014) Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler 20(11):1533–1540PubMedCrossRef
Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, Kim BJ et al (2014) Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 2014 71(11):1372–1378PubMedCrossRef
Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E et al (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66(9):1128–1133PubMedCrossRef
Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14PubMedPubMedCentralCrossRef
Jeong IH, Park B, Kim SH, Hyun JW, Joo J, Kim HJ (2016) Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler 22(3):329–339PubMedCrossRef
Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68(11):1412–1420PubMedCrossRef
Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70(9):1110–1117PubMedCrossRef
Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ, Hwang SH et al (2015) Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol 72(9):989–995PubMedCrossRef
Kim SM, Woodhall MR, Kim JS, Kim SJ, Park KS, Vincent A et al (2015) Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm 2(6):e163PubMedPubMedCentralCrossRef
Kleiter I, Hellwig K, Berthele A, Kumpfel T, Linker RA, Hartung HP et al (2012) Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69(2):239–245PubMedCrossRef
Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B et al (2016) Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 79(2):206–216PubMedCrossRef
Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106–2112PubMedCrossRef
Lin J, Xue B, Chen Z, Huang X, Pang W, Quan W et al (2016) Effects of early using azathioprine in the acute phase in neuromyelitis optica spectrum disorder. Int J Neurosci 4:1–8
Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71(3):324–330PubMedCrossRef
Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J et al (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76(15):1310–1315PubMedCrossRef
Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF et al (2013) Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 12(6):554–562PubMedCrossRef
Qiu W, Kermode AG, Li R, Dai Y, Wang Y, Wang J et al (2015) Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J Clin Neurosci 22(7):1178–1182PubMedCrossRef
Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stogbauer F et al (2015) Long-term therapy with Interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol 72(7):756–763PubMedCrossRef
Spadaro M, Gerdes LA, Krumbholz M, Ertl-Wagner B, Thaler FS, Schuh E et al (2016) Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 3(5):e257PubMedPubMedCentralCrossRef
Tenembaum S, Chitnis T, Nakashima I, Collongues N, McKeon A, Levy M et al (2016) Neuromyelitis optica spectrum disorders in children and adolescents. Neurology 87(9 Suppl 2): 59–66PubMedCrossRef
Trebst C, Berthele A, Jarius S, Kumpfel T, Schippling S, Wildemann B et al (2011a) Diagnosis and treatment of neuromyelitis optica : consensus recommendations of the neuromyelitis optica study group. Nervenarzt 82:768–777PubMedCrossRef
Trebst C, Raab P, Voss EV, Rommer P, Abu-Mugheisib M, Zettl UK et al (2011b) Longitudinal extensive transverse myelitis – it’s not all neuromyelitis optica. Nat Rev Neurol 7(12):688–698PubMedCrossRef
Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B et al (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261(1):1–16PubMedCrossRef
Wandinger KP, Stangel M, Witte T, Venables P, Charles P, Jarius S et al (2010) Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjogren’s syndrome. Arthritis Rheum 62(4):1198–2000PubMedCrossRef
Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW et al (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46(6):878–886PubMedCrossRef
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177–189PubMedPubMedCentralCrossRef
Wingerchuk DM (2007) Diagnosis and treatment of neuromyelitis optica. Neurologist 13(1):2–11PubMedCrossRef
Wingerchuk DM, Weinshenker BG (2008) Neuromyelitis optica. Curr Treat Options Neurol 10(1):55–66PubMedCrossRef
Yaguchi H, Sakushima K, Takahashi I, Nishimura H, Yashima-Yamada M, Nakamura M et al (2013) Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med 52(9):969–972PubMedCrossRef
Armangue T, Leypoldt F, Malaga I, Raspall-Chaure M, Marti I, Nichter C et al (2014) Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 75:317–323PubMedPubMedCentralCrossRef
Bauer J, Elger CE, Hans VH, Schramm J, Urbach H, Lassmann H, Bien CG (2007) Astrocytes are a specific immunological target in Rasmussen’s encephalitis. Ann Neurol 62(1):67–80PubMedCrossRef
Bien CG, Schulze-Bonhage A, Deckert M, Urbach H, Helmstaedter C, Grunwald T, Schaller C, Elger CE (2000) Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy. Neurology 55(12):1823–1828PubMedCrossRef
Bien CG, Gleissner U, Sassen R, Widman G, Urbach H, Elger CE (2004) An open study of tacrolimus therapy in Rasmussen encephalitis. Neurology 62(11):2106–2109PubMedCrossRef
Bien CG, Granata T, Antozzi C, Cross JH, Dulac O, Kurthen M, Lassmann H, Mantegazza R, Villemure JG, Spreafico R, Elger CE (2005) Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 128(Pt 3):454–471PubMedCrossRef
Brierley JB, Corsellis JAN, Hierons R, Nevin S (1960) Subacute encephalitis of later adult life mainly affecting the limbic areas. Brain 83:357–368CrossRef
Buckley C, Oger J, Clover L, Tüzün E, Carpenter K, Jackson M, Vincent A (2001) Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 50(1):73–78PubMedCrossRef
Chinchilla D, Dulac O, Robain O, Plouin P, Ponsot G, Pinel JF, Graber D (1994) Reappraisal of Rasmussen’s syndrome with special emphasis on treatment with high doses of steroids. J Neurol Neurosurg Psychiatry 57(11):1325–1333PubMedPubMedCentralCrossRef
Corsellis JA, Goldberg GJ, Norton AR (1968) „Limbic encephalitis“ and its association with carcinoma. Brain 91(3):481–496PubMedCrossRef
Dalmau J (2008) Limbic encephalitis and variants related to neuronal cell membrane autoantigens. Rinsho Shinkeigaku 48(11):871–874PubMedCrossRef
Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7(12):1091–1098PubMedPubMedCentralCrossRef
Dogan OM, Deuretzbacher D, Haensch CA, Hagedorn HJ, Halve S, Isenmann S et al (2015) Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series. J Neurol Neurosurg Psychiatry 86:965–972CrossRef
Gold M, Pul R, Bach JP, Stangel M, Dodel R (2012) Pathogenic and physiological autoantibodies in the central nervous system. Immunol Rev 248:68–86PubMedCrossRef
Granata T, Fusco L, Gobbi G, Freri E, Ragona F, Broggi G, Mantegazza R, Giordano L, Villani F, Capovilla G, Vigevano F, Bernardina BD, Spreafico R, Antozzi C (2003a) Experience with immunomodulatory treatments in Rasmussen’s encephalitis. Neurology 61(12):1807–1810PubMedCrossRef
Granata T, Gobbi G, Spreafico R, Vigevano F, Capovilla G, Ragona F, Freri E, Chiapparini L, Bernasconi P, Giordano L, Bertani G, Casazza M, Dalla Bernardina B, Fusco L (2003b) Rasmussen’s encephalitis: early characteristics allow diagnosis. Neurology 60(3):422–425PubMedCrossRef
Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D et al (2010) Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 10:835–844PubMedCrossRef
Graus F, Saiz A, Lai M, Bruna J, López F, Sabater L, Blanco Y, Rey MJ, Ribalta T, Dalmau J (2008) Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology 71(12):930–936PubMedPubMedCentralCrossRef
Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391–404PubMedPubMedCentralCrossRef
Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J (2000) Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123(Pt 7):1481–1494PubMedCrossRef
Hart YM, Cortez M, Andermann F, Hwang P, Fish DR, Dulac O, Silver K, Fejerman N, Cross H, Sherwin A et al (1994) Medical treatment of Rasmussen’s syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 44(6):1030–1036PubMedCrossRef
Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A (2010) Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 133(9):2734–2748PubMedPubMedCentralCrossRef
Jeffery OJ, Lennon VA, Pittock SJ, Gregory JK, Britton JW, McKeon A (2013) GABAB receptor autoantibody frequency in service serologic evaluation. Neurology 81:882–887PubMedPubMedCentralCrossRef
Johnson N, Henry C, Fessler AJ, Dalmau J (2010) Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology 75(16):1480–1482PubMedPubMedCentralCrossRef
Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, Friedman D, Skeen MB, Grisold W, Kimura A, Ohta K, Iizuka T, Guzman M, Graus F, Moss SJ, Balice-Gordon R, Dalmau J (2010) Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 9(1):67–76PubMedCrossRef
Leypoldt F, Armangue T, Dalmau J (2015) Autoimmune encephalopathies. Ann N Y Acad Sci 1338:94–114PubMedCrossRef
Liguori R, Vincent A, Clover L, Avoni P, Plazzi G, Cortelli P, Baruzzi A, Carey T, Gambetti P, Lugaresi E, Montagna P (2001) Morvan’s syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124(Pt 12):2417–2426PubMedCrossRef
Linke R, Schroeder M, Helmberger T, Voltz R (2004) Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 63(2):282–286PubMedCrossRef
Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG (2010) Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 67(4):470–478PubMedCrossRef
Mantegazza R, Bernasconi P, Baggi F, Spreafico R, Ragona F, Antozzi C, Bernardi G, Granata T (2002) Antibodies against GluR3 peptides are not specific for Rasmussen’s encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol 131(1–2):179–185PubMedCrossRef
Martinez-Hernandez E, Arino H, McKeon A, Iizuka T, Titulaer MJ, Simabukuro MM et al (2016) Clinical and immunologic investigations in patients with Stiff-Person spectrum disorder. JAMA Neurol 73:714–720PubMedPubMedCentralCrossRef
Matà S, Muscas GC, Naldi I, Rosati E, Paladini S, Cruciatti B, Bisulli F, Paganini M, Mazzi G, Sorbi S, Tinuper PJ (2008) Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. Neuroimmunol 199(1–2):155–159CrossRef
Mori M, Kuwabara S, Yoshiyama M, Kanesaka T, Ogata T, Hattori T (2002) Successful immune treatment for non-paraneoplastic limbic encephalitis. J Neurol Sci 201(1–2):85–88PubMedCrossRef
Oguni H, Andermann F, Rasmussen TB (1992) The syndrome of chronic encephalitis and epilepsy. A study based on the MNI series of 48 cases. Adv Neurol 57:419–433PubMed
Quartuccio N, Caobelli F, Evangelista L, Alongi P, Kirienko M, De BV et al (2015) The role of PET/CT in the evaluation of patients affected by limbic encephalitis: a systematic review of the literature. J Neuroimmunol 284:44–48PubMedCrossRef
Sansing LH, Tüzün E, Ko MW, Baccon J, Lynch DR, Dalmau J (2007) A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol 3(5):291–296PubMedPubMedCentralCrossRef
Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D (2012) Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 79:1094–1100PubMedPubMedCentralCrossRef
Sonderen A van, Arino H, Petit-Pedrol M, Leypoldt F, Kortvelyessy P, Wandinger KP et al (2016) The clinical spectrum of Caspr2 antibody-associated disease. Neurology 87(5):521–528PubMedPubMedCentralCrossRef
Tobias SM, Robitaille Y, Hickey WF, Rhodes CH, Nordgren R, Andermann F (2003) Bilateral Rasmussen encephalitis: postmortem documentation in a five-year-old. Epilepsia 44(1):127–130PubMedCrossRef
Urbach H, Sassen R, Soeder BM, Flacke S, Becker A, Bien CG (2006a) Serial MRI in patients with aquired hippocampal sclerosis. Clin Neuroradiol 16:47–52CrossRef
Urbach H, Soeder BM, Jeub M, Klockgether T, Meyer B, Bien CG (2006b) Serial MRI of limbic encephalitis. Neuroradiology 48(6):380–386PubMedCrossRef
Villani F, Pincherle A, Antozzi C, Chiapparini L, Granata T, Michelucci R, Rubboli G, Simone I, Bellomo R, Spreafico R (2006) Adult-onset Rasmussen’s encephalitis: anatomical-electrographic-clinical features of 7 Italian cases. Epilepsia 47(Suppl 5):41–46PubMedCrossRef
Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, Clover L, Parkinson A, Bien CG, Omer S, Lang B, Rossor MN, Palace J (2004) Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127(Pt 3):701–712PubMedCrossRef
Watson R, Jiang Y, Bermudez I, Houlihan L, Clover L, McKnight K, Cross JH, Hart IK, Roubertie A, Valmier J, Hart Y, Palace J, Beeson D, Vincent A, Lang B (2004) Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology 63(1):43–50PubMedCrossRef
Younes-Mhenni S, Janier MF, Cinotti L, Antoine JC, Tronc F, Cottin V, Ternamian PJ, Trouillas P, Honnorat J (2004) FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 127(Pt 10):2331–2338PubMedCrossRef
Zuliani L, Saiz A, Tavolato B, Giometto B, Vincent A, Graus F (2007) Paraneoplastic limbic encephalitis associated with potassium channel antibodies: value of anti-glial nuclear antibodies in identifying the tumour. J Neurol Neurosurg Psychiatry 78(2):204–205PubMedPubMedCentralCrossRef
Metadaten
Titel
Multiple Sklerose und andere autoimmune ZNS-Erkrankungen
verfasst von
Martin Stangel
Christoph Kleinschnitz
Mathias Mäurer
Peter Raab
Kurt-Wolfram Sühs
Corinna Trebst
Copyright-Jahr
2018
Verlag
Springer Berlin Heidelberg
Buch
Autoimmunerkrankungen in der Neurologie

Print ISBN: 978-3-662-55529-3

Electronic ISBN: 978-3-662-55530-9

Copyright-Jahr: 2018

DOI
https://doi.org/10.1007/978-3-662-55530-9_1

Neu in den Fachgebieten Neurologie und Psychiatrie

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus
Professorin Dr. Claudia Trenkwalder, Neurologin

23.04.2024 | Depression antepartal oder postpartal | Nachrichten

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein